Tonsillectomy Improved Therapeutic Response in Anti-SRP Myopathy With Chronic Tonsillitis

Front Immunol. 2020 Nov 24:11:595480. doi: 10.3389/fimmu.2020.595480. eCollection 2020.

Abstract

Chronic tonsillitis has been attracted attention as a source of abnormal immune responses and a possible trigger of autoimmune diseases such as IgA nephritis, IgA vasculitis, palmoplantar pustulosis, psoriasis, rheumatoid arthritis, Behçet's disease, and myositis. Here we present the first report of anti-signal recognition particle antibody-associated necrotizing myopathy (anti-SRP myopathy) with IgA nephropathy and chronic tonsillitis in which the therapeutic response to intravenous immunoglobulin (IVIG) treatment was dramatically improved after tonsillectomy and accompanied by a rapid increase in ΔIgG, defined as the change in serum IgG levels 2 weeks after the start of IVIG treatment relative to pre-treatment levels. Moreover, serum anti-SRP antibody titers became undetectable after tonsillectomy even though the resected tonsils did not produce anti-SRP antibodies. Tonsillectomy should be considered when chronic tonsillitis is observed in patients with autoimmune diseases showing poor response to treatment, including anti-SRP myopathy.

Keywords: IgA nephritis; anti-SRP myopathy; chronic tonsillitis; intravenous immunoglobulin; tonsillectomy.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chronic Disease
  • Female
  • Glomerulonephritis, IGA / drug therapy
  • Glomerulonephritis, IGA / surgery*
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Middle Aged
  • Muscular Diseases / drug therapy
  • Muscular Diseases / surgery*
  • Signal Recognition Particle / immunology*
  • Tonsillectomy*
  • Tonsillitis / drug therapy
  • Tonsillitis / surgery*

Substances

  • Immunoglobulins, Intravenous
  • Signal Recognition Particle